Table 2.
Number of studies with statistically significant differences in AEFI after co-administration compared to separate administration.
| Vaccines Co-Administered | Number of Studies | AEFI | Stat. Sign. More AEFI | Stat. Sign. Fewer AEFI | No Stat. Sign. Difference |
|---|---|---|---|---|---|
| DTaP-HepB-IPV/Hib + MenC | 1 | Injection site erythema | 0 (0%) | 1 (100%) | 0 (0%) |
| DTaP-HepB-IPV/Hib + PCV7 | 3 | Pyrexia | 1 (33%) | 0 (0%) | 2 (67%) |
| DTaP-IPV + RV5 | 1 | Diarrhoea | 0 (0%) | 1 (100%) | 0 (0%) |
| Pyrexia | 0 (0%) | 1 (100%) | 0 (0%) | ||
| DTaP-IPV/Hib + MenC + RV | 1 | Vomiting | 1 (100%) | 0 (0%) | 0 (0%) |
| DTaP-IPV/Hib + MMR | 1 | Overall | 1 (100%) | 0 (0%) | 0 (0%) |
| MenACWY + Tdap + HPV | 4 | Injection site bruising | 1 (25%) | 0 (0%) | 3 (75%) |
| Injection site pain | 1 (25%) | 0 (0%) | 3 (75%) | ||
| Injection site swelling | 1 (25%) | 0 (0%) | 3 (75%) | ||
| Myalgia | 1 (25%) | 0 (0%) | 3 (75%) | ||
| MMR + VAR + Hib-HepB | 1 | Rash | 0 (0%) | 1 (100%) | 0 (0%) |
| Rhinorrhoea | 0 (0%) | 1 (100%) | 0 (0%) | ||
| OPV + LAIV | 1 | Conjunctivitis | 0 (0%) | 1 (100%) | 0 (0%) |
| PCV7 + MMRV | 1 | Insomnia | 0 (0%) | 1 (100%) | 0 (0%) |
| Nasopharyngitis | 0 (0%) | 1 (100%) | 0 (0%) | ||
| PCV13 + IIV3 | 1 | Pyrexia | 1 (100%) | 0 (0%) | 0 (0%) |
| Td + MMR + HepB | 1 | Headache | 1 (100%) | 0 (0%) | 0 (0%) |
| Injection site tenderness | 1 (100%) | 0 (0%) | 0 (0%) |